|
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for
|
4R42CA171552-02
|
$924,745
|
|
DESAI, NEIL
|
AADI, LLC
|
|
Activin A antagonist for treatment of cancer-associated cachexia
|
1R43CA203180-01
|
$225,000
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes.
|
2R44CA180296-02
|
$792,080
|
|
STRAIGHT, BRIAN
|
AKROTOME IMAGING, INC.
|
|
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
|
7R21CA175802-03
|
$171,825
|
|
ROBEK, MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
6U01CA078527-18
|
$581,591
|
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
3U54CA163131-04S1
|
$20,366
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
3U54CA163131-05S1
|
$54,254
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
6U54CA163131-05
|
$426,161
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
|
6R01CA148966-06
|
$1
|
|
EINSTEIN, MARK
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of macroH2A variants in cancer and senescence
|
6R01CA155232-05
|
$282,166
|
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
6R01CA082621-18
|
$486,473
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Rac1 regulates protrusion and invasion of breast cancers in 3D
|
6R21CA181838-03
|
$217,935
|
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
1T32CA200561-01
|
$132,211
|
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
6R01CA170911-05
|
$346,525
|
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
6R01CA160790-05
|
$522,889
|
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Novel approach to study intravasation in primary human breast cancer cells(PQ24)
|
6R01CA170507-05
|
$352,567
|
|
OKTAY, MAJA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
6R01CA154755-06
|
$53,995
|
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
6R01CA172451-04
|
$1
|
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Risk for Lung Cancer Asthma and COPD; Integrating Clinical and Airway Biomarker
|
6K24CA139054-06
|
$46,641
|
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Exhaled microRNAs leveraged for lung cancer risk assessment
|
6R21CA192168-02
|
$168,684
|
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
In Vivo Multiphoton Based Imaging of Complex Cancer Cell Behavior
|
6R01CA164468-06
|
$753,636
|
|
VERKHUSHA, VLADISLAV
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Development of an automated Umbilical Cord Blood Hematopoietic Stem Cell expansio
|
1R43CA200369-01
|
$185,500
|
|
NOLAN, DANIEL
|
ANGIOCRINE BIOSCIENCE, INC.
|
|
Stand and Move at Work: A Group-Randomized Trial
|
1R01CA198971-01
|
$639,042
|
|
BUMAN, MATTHEW
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
1R01CA199948-01
|
$517,230
|
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Mitochondria-nuclear crosstalk in triple negative breast cancer racial disparity
|
3R21CA179720-02S1
|
$53,212
|
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitochondria-nuclear crosstalk in triple negative breast cancer racial disparity
|
3R21CA179720-02S2
|
$199,986
|
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
In Vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xen
|
1U01CA199288-01
|
$604,258
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
1R01CA190467-01A1
|
$362,569
|
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Prospective Identification of Translational Regulators in EMT
|
1R21CA185769-01A1
|
$206,843
|
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Notch Signaling in Prostate Homeostasis and Carcinogenesis
|
1R01CA190378-01A1
|
$362,569
|
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Control of tumor growth and metastasis by the cytokine TSLP
|
3R01CA182783-02S1
|
$94,680
|
|
ZIEGLER, STEVEN
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
1U01CA199252-01
|
$1,080,326
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)
|
1R44CA203221-01
|
$808,983
|
|
HUPERT, MATEUSZ
|
BIOFLUIDICA, INC
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy
|
1R44CA203068-01
|
$299,876
|
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
1U01CA187508-01A1
|
$498,385
|
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Enzyme-instructed self-assembly for molecular anticancer nanomedicines
|
2R01CA142746-06A1
|
$383,751
|
|
XU, BING
|
BRANDEIS UNIVERSITY
|
|
Murine Models on SALL4 in Hepatocellular Carcinoma
|
1R03CA184531-01A1
|
$81,724
|
|
CHAI, LI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Systematic identification of oncogenic KRAS synthetic lethal interactions
|
1U01CA199253-01
|
$817,805
|
|
HAHN, WILLIAM
|
BROAD INSTITUTE, INC.
|
|
Genome Characterization Center (GCC)
|
3U24CA143867-05S2
|
$364,797
|
|
MEYERSON, MATTHEW
|
BROAD INSTITUTE, INC.
|
|
Theranostic nanoparticles for dual modality cancer therapy
|
1SC2CA206194-01A1
|
$157,000
|
|
CZAJKOWSKA, ANETA
|
BROOKLYN COLLEGE
|
|
Using Behavioral Economics to Promote Exercise among Inactive Overweight Adults
|
1R03CA188473-01A1
|
$81,250
|
|
WILLIAMS, DAVID
|
BROWN UNIVERSITY
|
|
Risk factors for breast cancer subtypes in racial/ethnic minorities
|
1R03CA199343-01
|
$74,500
|
|
JOHN, ESTHER
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer
|
4R44CA176937-02
|
$903,055
|
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
PET Kinetic Modeling of Inhibiting Glycolysis in Ovarian Cancer
|
1R21CA198795-01
|
$185,247
|
|
AVRIL, NORBERT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor
|
1R21CA187695-01A1
|
$217,926
|
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Identifying a network of miRNAs and genes that regulate breast tumor metastasis
|
3R00CA160638-03S1
|
$57,024
|
|
LIU, HUIPING
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Pathology Image Informatics Platform for visualization, analysis and management
|
1U24CA199374-01
|
$606,305
|
|
MADABHUSHI, ANANT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Natural Agent in Prevention of Prostate Cancer
|
1R21CA190921-01A1
|
$172,369
|
|
SHUKLA, SANJEEV
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Protein-DNA Drug Carriers for Targeting Drug-Resistant Tumors
|
2R01CA129822-05A1
|
$374,063
|
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
Total relevant funding to Inflammatory Bowel Disease for this search: $3,102,212
|